26 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors.
F. Hoffmann-La Roche
The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation.
Chinese Academy of Sciences
Novel fatty acid binding protein 4 (FABP4) inhibitors: virtual screening, synthesis and crystal structure determination.
Chinese Academy of Sciences
Interaction kinetics of liposome-incorporated unsaturated fatty acids with fatty acid-binding protein 3 by surface plasmon resonance.
Osaka University
Structure-guided design, synthesis and in vitro evaluation of a series of pyrazole-based fatty acid binding protein (FABP) 3 ligands.
Okayama University 1-1-1
New aromatic substituted pyrazoles as selective inhibitors of human adipocyte fatty acid-binding protein.
Chinese Academy of Sciences
Discovery of highly selective inhibitors of human fatty acid binding protein 4 (FABP4) by virtual screening.
Chinese Academy of Sciences
Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins.
University of Minnesota
N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors.
Biovitrum
Recent Advances on Small-Molecule Inhibitors of Lipocalin-like Proteins.
Sichuan University
Design, synthesis, and biological evaluation of first-in-class FABP1 inhibitors for the treatment of NASH.
Guangdong Pharmaceutical University
Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP).
Bristol-Myers Squibb Pharmaceutical Research Institute
Truxillic acid monoamides as fatty acid binding protein 5 inhibitors.
Stony Brook University
Optimization of potent, selective and orally bioavailable biphenyl scaffold as FABP4 inhibitors for anti-inflammation.
Fudan University
Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease.
Guangdong Pharmaceutical University
Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review.
Universita degli Studi di Catania
Substituted benzylamino-6-(trifluoromethyl)pyrimidin-4(1H)-ones: a novel class of selective human A-FABP inhibitors.
Biovitrum
Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target.
Biovitrum
Development of FABP4/5 inhibitors with potential therapeutic effect on type 2 Diabetes Mellitus.
Fudan University
Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation.
Chinese Academy of Sciences
Identification of new dual FABP4/5 inhibitors based on a naphthalene-1-sulfonamide FABP4 inhibitor.
Fudan University
SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins.
Stony Brook University
From hit to lead: Structure-based discovery of naphthalene-1-sulfonamide derivatives as potent and selective inhibitors of fatty acid binding protein 4.
Fudan University
